AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27352003 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols (DM and DMB)
Number of subjects: 16
Study 25376431 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured Tuohy needle
Number of subjects: 144
Study 25376431 — intervention group
Group type: EXPERIMENTAL
Intervention: Textured single-shot needle
Number of subjects: 144
Study 25376431 — intervention group
Group type: COMPARATOR
Intervention: Smooth-surfaced Tuohy needle
Number of subjects: 144
Study 23984433 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity interval exercise (HI‐IE)
Number of subjects: 15
Study 23984433 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity continuous exercise (MI‐CE)
Number of subjects: 15
Study 19783056 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 308
Study 19783056 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 308
Study 19783056 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 308
Study 19260398 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based course
Number of subjects: 147
Study 19260398 — intervention group
Group type: COMPARATOR
Intervention: Traditional classroom teaching
Number of subjects: 147
Study 17096616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed heart disease prevention message
Number of subjects: 395
Study 17096616 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed heart disease prevention message
Number of subjects: 395
Study 17096616 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message for women with parental risk factors
Number of subjects: 395
Study 17096616 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message for women with parental risk factors
Number of subjects: 395
Study 15677411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) + Diet for 6 weeks
Number of subjects: 22
Study 15677411 — intervention group
Group type: COMPARATOR
Intervention: Wait-List (WL) control group
Number of subjects: 22
Study 15677411 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) + Diet
Number of subjects: 22
Study 11350261 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT (long chain triglycerides, corn oil)
Number of subjects: 7
Study 11350261 — intervention group
Group type: EXPERIMENTAL
Intervention: VLCT (very long chain triglycerides, fish oil)
Number of subjects: 7
Study 11350261 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (medium chain triglycerides) 15 mL h(‐1)
Number of subjects: 7
Study 11350261 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT (medium chain triglycerides) 30 mL h(‐1)
Number of subjects: 7
Study 11350261 — intervention group
Group type: COMPARATOR
Intervention: MCT (medium chain triglycerides)
Number of subjects: 7
Study 9448125 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon sphincteroplasty (EBS)
Number of subjects: 33
Study 9448125 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic balloon sphincteroplasty (EBS) combined with laparoscopic cholecystectomy (LC)
Number of subjects: 33
Study 7639370 — intervention group
Group type: EXPERIMENTAL
Intervention: Single injection of 25 mL of 0.75% bupivacaine
Number of subjects: 30
Study 7639370 — intervention group
Group type: COMPARATOR
Intervention: Staged injection of 25 mL of 0.75% bupivacaine
Number of subjects: 30
Study 30924845 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter transposition (LT) technique with initial transpositions
Number of subjects: 18
Study 30924845 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter transposition (LT) technique with internal transpositions
Number of subjects: 18
Study 30924845 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter transposition (LT) technique with final transpositions
Number of subjects: 18
Study 30924845 — intervention group
Group type: EXPERIMENTAL
Intervention: Letter transposition (LT) technique
Number of subjects: 18
Study 27885554 — intervention group
Group type: EXPERIMENTAL
Intervention: Active gum
Number of subjects: 57
Study 27885554 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 57
Study 27885554 — intervention group
Group type: COMPARATOR
Intervention: No gum
Number of subjects: 57
Study 27470449 — intervention group
Group type: EXPERIMENTAL
Intervention: CTA and selective FFRCT (n = 297)
Number of subjects: 584
Study 27470449 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 287)
Number of subjects: 584
Study 27470449 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT (cost weight of zero)
Number of subjects: 584
Study 27470449 — intervention group
Group type: COMPARATOR
Intervention: Usual care (cost weight of zero)
Number of subjects: 584
Study 27470449 — intervention group
Group type: EXPERIMENTAL
Intervention: FFRCT (noninvasive stratum)
Number of subjects: 584
Study 27470449 — intervention group
Group type: COMPARATOR
Intervention: Usual care (noninvasive stratum)
Number of subjects: 584
Study 25170121 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) plus corticosteroids
Number of subjects: 372
Study 25170121 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroids alone (placebo)
Number of subjects: 372
Study 22100189 — intervention group
Group type: EXPERIMENTAL
Intervention: Aquacel(®) Ag
Number of subjects: 40
Study 22100189 — intervention group
Group type: COMPARATOR
Intervention: MEBO(®)
Number of subjects: 40
Study 20473734 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy with Jinlong Capsule (JLC) and transcatheter arterial chemoembolization (TACE)
Number of subjects: 98
Study 20473734 — intervention group
Group type: COMPARATOR
Intervention: Transcatheter arterial chemoembolization (TACE) only
Number of subjects: 98
Study 19808281 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional intervention (repetitive education and telephone monitoring)
Number of subjects: 350
Study 19808281 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 350
Study 17002635 — intervention group
Group type: EXPERIMENTAL
Intervention: S-303 treated RBCs after a single transfusion (Study 1A)
Number of subjects: 99
Study 17002635 — intervention group
Group type: EXPERIMENTAL
Intervention: S-303 treated RBCs after multiple transfusions (Study 1B)
Number of subjects: 99
Study 17002635 — intervention group
Group type: COMPARATOR
Intervention: S-303 RBCs (Study 1C)
Number of subjects: 99
Study 17002635 — intervention group
Group type: COMPARATOR
Intervention: Conventional RBCs (Study 1C)
Number of subjects: 99
Study 17002635 — intervention group
Group type: EXPERIMENTAL
Intervention: S-303 RBCs (Studies 1A and 1B)
Number of subjects: 99
Study 12728024 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment (posterior or anterior arthrodesis and instrumentation)
Number of subjects: 47
Study 12728024 — intervention group
Group type: COMPARATOR
Intervention: Nonoperative treatment (application of a body cast or orthosis)
Number of subjects: 47
Study 12728024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 47
Study 10834683 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate
Number of subjects: 20
Study 10834683 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 20
Study 8772681 — intervention group
Group type: EXPERIMENTAL
Intervention: c7E3 Fab (antiplatelet IIb/IIIa receptor antibody)
Number of subjects: 2038
Study 1597603 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-standard discrimination task with a 500-ms interstimulus interval
Number of subjects: 0
Study 1597603 — intervention group
Group type: EXPERIMENTAL
Intervention: Random-standard discrimination task with an 8-s interstimulus interval
Number of subjects: 0
Study 1597603 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification task
Number of subjects: 0
Study 1597603 — intervention group
Group type: EXPERIMENTAL
Intervention: Modulation rates above 100 Hz using 500- to 1600-Hz noise band
Number of subjects: 0
Study 1597603 — intervention group
Group type: EXPERIMENTAL
Intervention: General modulation rate perception
Number of subjects: 0
Study 6321195 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 10
Study 6321195 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 10
Study 6321195 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Propranolol
Number of subjects: 10
Study 29458237 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (80 mg/m2, days 1 and 8) plus capecitabine (1,000 mg/m2 twice a day, days 1-14)
Number of subjects: 221
Study 29458237 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone (1,250 mg/m2 twice a day, days 1-14)
Number of subjects: 221
Study 29458237 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus capecitabine in triple-negative breast cancer (TNBC, n=90)
Number of subjects: 221
Study 29458237 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone in triple-negative breast cancer (TNBC, n=90)
Number of subjects: 221
Study 29458237 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan plus capecitabine
Number of subjects: 221
Study 29458237 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine alone
Number of subjects: 221
Study 29393675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas
Number of subjects: 35
Study 29393675 — intervention group
Group type: COMPARATOR
Intervention: Single-hormone artificial pancreas
Number of subjects: 35
Study 29393675 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-hormone artificial pancreas (hypoglycemia awareness)
Number of subjects: 35
Study 29393675 — intervention group
Group type: COMPARATOR
Intervention: Single-hormone artificial pancreas (hypoglycemia awareness)
Number of subjects: 35
Study 26741052 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical naltrexone (1 drop, 4 drops) at dosages of 1 × 10(‐6) M, 5 × 10(‐6) M, 1 × 10(‐5) M, 5 × 10(‐5) M
Number of subjects: 20
Study 26741052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 drop)
Number of subjects: 20
Study 25005652 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (varenicline + nicotine patch)
Number of subjects: 446
Study 25005652 — intervention group
Group type: COMPARATOR
Intervention: Varenicline alone
Number of subjects: 446
Study 23270509 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care and standard care
Number of subjects: 88
Study 23270509 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 88
Study 21062129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) plus Ivermectin (200 μg/kg)
Number of subjects: 548
Study 21062129 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) plus Ivermectin (200 μg/kg)
Number of subjects: 548
Study 21062129 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (500 mg) plus placebo
Number of subjects: 548
Study 21062129 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg) plus placebo
Number of subjects: 548
Study 21062129 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin (200 μg/kg)
Number of subjects: 548
Study 17958720 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-reflux stent (n = 24, group 2)
Number of subjects: 49
Study 17958720 — intervention group
Group type: COMPARATOR
Intervention: Standard stent (n = 25, group 1)
Number of subjects: 49
Study 15736010 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 139
Study 15736010 — intervention group
Group type: COMPARATOR
Intervention: Macrolides
Number of subjects: 139
Study 12492193 — intervention group
Group type: EXPERIMENTAL
Intervention: Balsalazide 6.75 g/day
Number of subjects: 173
Study 12492193 — intervention group
Group type: COMPARATOR
Intervention: Mesalamine 2.4 g/day
Number of subjects: 173
Study 9818039 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic imaging (3.5-MHz receive mode)
Number of subjects: 29
Study 9818039 — intervention group
Group type: COMPARATOR
Intervention: Fundamental imaging at 2.0 MHz
Number of subjects: 29
Study 9818039 — intervention group
Group type: COMPARATOR
Intervention: Fundamental imaging at 3.5 MHz
Number of subjects: 29
Study 9818039 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic imaging
Number of subjects: 29
Study 7649071 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of trihexyphenidyle (group I)
Number of subjects: 101
Study 7649071 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive withdrawal of trihexyphenidyle for 2 weeks (group II)
Number of subjects: 101
Study 7649071 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment with trihexyphenidyle (group III)
Number of subjects: 101
Study 2539772 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymostimulin (1 mg/Kg i.m., days 7-14 of every cycle)
Number of subjects: 26
Study 2539772 — intervention group
Group type: COMPARATOR
Intervention: Control (without thymostimulin)
Number of subjects: 26
Study 334808 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg
Number of subjects: 20
Study 334808 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 334808 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin 100 mg every 8 hours for two weeks
Number of subjects: 20
Study 334808 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 20
Study 31382986 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole brain radiotherapy (WBRT)
Number of subjects: 0
Study 31382986 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0
Study 26865602 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 40 mg twice a day for 2 months with prayer (group B)
Number of subjects: 92
Study 26865602 — intervention group
Group type: COMPARATOR
Intervention: Propranolol 40 mg twice a day for 2 months (group A)
Number of subjects: 92
Study 25730171 — intervention group
Group type: EXPERIMENTAL
Intervention: Mintz bibliotherapy intervention
Number of subjects: 45
Study 25730171 — intervention group
Group type: EXPERIMENTAL
Intervention: Hall self-help book
Number of subjects: 45
Study 25730171 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WLC) group
Number of subjects: 45
Study 23608721 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 IU of daily vitamin D3
Number of subjects: 56
Study 23608721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 IU of daily vitamin D3
Number of subjects: 56
Study 23608721 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 56
Study 21875209 — intervention group
Group type: EXPERIMENTAL
Intervention: Expressive writing intervention group
Number of subjects: 179
Study 21875209 — intervention group
Group type: COMPARATOR
Intervention: Control group (neutral writing)
Number of subjects: 179
Study 19793473 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin 1g intravenously after induction of anesthesia (group 1)
Number of subjects: 144
Study 19793473 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics (group 2)
Number of subjects: 144
Study 16455437 — intervention group
Group type: EXPERIMENTAL
Intervention: Story-centered care
Number of subjects: 24
Study 16455437 — intervention group
Group type: COMPARATOR
Intervention: Standard lifestyle intervention
Number of subjects: 24
Study 12958610 — intervention group
Group type: EXPERIMENTAL
Intervention: Triacylglycerol infusion [1.5 ml/min]/heparin [0.2 IU/(kg.min)] (LIP)
Number of subjects: 10
Study 12958610 — intervention group
Group type: COMPARATOR
Intervention: Saline only (SAL)
Number of subjects: 10
Study 12958610 — intervention group
Group type: COMPARATOR
Intervention: Saline/heparin (HEP)
Number of subjects: 10
Study 11200830 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 20
Study 11200830 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study 9177404 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 236
Study 9177404 — intervention group
Group type: COMPARATOR
Intervention: Calcium Supplementation (CS; 500 mg/day)
Number of subjects: 236
Study 9177404 — intervention group
Group type: COMPARATOR
Intervention: Calcium Supplementation (CS)
Number of subjects: 236
Study 1447382 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine rinse (positive control)
Number of subjects: 15
Study 1447382 — intervention group
Group type: COMPARATOR
Intervention: saline rinse (negative control)
Number of subjects: 15
Study 1447382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguinarine rinse
Number of subjects: 15
Study 1447382 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguinarine rinse with zinc
Number of subjects: 15
Study 1447382 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan/SLS rinses
Number of subjects: 15
Study 1447382 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural product/SLS experimental rinse
Number of subjects: 15
Study 3522483 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of acetylsalicylic acid
Number of subjects: 27
Study 3522483 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 31078956 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor sleep efficiency
Number of subjects: 338
Study 31078956 — intervention group
Group type: COMPARATOR
Intervention: Apnea-hypopnea index (AHI)
Number of subjects: 338
Study 31078956 — intervention group
Group type: COMPARATOR
Intervention: Sleep quality
Number of subjects: 338
Study 29092985 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncemented peri-apatite-coated TKA
Number of subjects: 60
Study 29092985 — intervention group
Group type: COMPARATOR
Intervention: Cemented TKA
Number of subjects: 60
Study 26387144 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4922
Study 26387144 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4922
Study 23620943 — intervention group
Group type: EXPERIMENTAL
Intervention: TCM herbal cupping therapy
Number of subjects: 57
Study 23620943 — intervention group
Group type: COMPARATOR
Intervention: Thermal compressing therapy
Number of subjects: 57
Study 23620943 — intervention group
Group type: COMPARATOR
Intervention: Mecobalamine (western medicine)
Number of subjects: 57
Study 21480107 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 μg of hepatitis B vaccine intramuscularly at birth (0), 2 and 9‐12 months of life
Number of subjects: 64
Study 21480107 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B vaccine at 0, 1 and 6 months of life
Number of subjects: 64
Study 21480107 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 64
Study 19149069 — intervention group
Group type: EXPERIMENTAL
Intervention: Round bar design with resilient anchorage (group 1)
Number of subjects: 51
Study 19149069 — intervention group
Group type: COMPARATOR
Intervention: Milled bar design with rigid anchorage (group 2)
Number of subjects: 51
Study 16492925 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of energy intake (> or = 2,084 kcal/d)
Number of subjects: 38660
Study 16492925 — intervention group
Group type: EXPERIMENTAL
Intervention: Current body mass index (BMI >30 kg/m2)
Number of subjects: 38660
Study 16492925 — intervention group
Group type: COMPARATOR
Intervention: Vigorous recreational physical activity (> or = 4 hours/wk)
Number of subjects: 38660
Study 16492925 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable energy balance (highest energy intake, highest BMI, least physical activity)
Number of subjects: 38660
Study 14633652 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-150 mg/day)
Number of subjects: 83
Study 14633652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study 11737121 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg once daily)
Number of subjects: 154
Study 11737121 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (10 mg once daily)
Number of subjects: 154
Study 9438490 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.16 ppm ozone
Number of subjects: 8
Study 9438490 — intervention group
Group type: COMPARATOR
Intervention: Clean air
Number of subjects: 8
Study 8249784 — intervention group
Group type: COMPARATOR
Intervention: Control (nonpreconditioned) + vehicle
Number of subjects: 4
Study 8249784 — intervention group
Group type: COMPARATOR
Intervention: Control + DCF
Number of subjects: 4
Study 8249784 — intervention group
Group type: COMPARATOR
Intervention: Preconditioned + vehicle
Number of subjects: 4
Study 8249784 — intervention group
Group type: COMPARATOR
Intervention: Preconditioned + DCF
Number of subjects: 4
Study 8249784 — intervention group
Group type: EXPERIMENTAL
Intervention: Preconditioned groups (both vehicle and DCF)
Number of subjects: 4
Study 3677969 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 24
Study 3677969 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 28796128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer (Tabata protocol [TBT]; eight 20‐second bouts at 170% Pmax interspersed by 10‐second rest)
Number of subjects: 12
Study 28796128 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body calisthenic exercises (McRae protocol; eight 20‐second all‐out intervals interspersed by 10‐second rest)
Number of subjects: 12
Study 28796128 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle ergometer (Tabata protocol [TBT])
Number of subjects: 12
Study 26784016 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 46
Study 26784016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 24576196 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration (15 mcg/m(2) s.c. three times weekly during week 1, 30 mcg/m(2) s.c. three times weekly during week 2, followed by 50 mcg/m(2) s.c. three times weekly during week 3)
Number of subjects: 40
Study 24576196 — intervention group
Group type: COMPARATOR
Intervention: No Titration (full 50 mcg/m(2) s.c. three times weekly for 3 weeks)
Number of subjects: 40
Study 24576196 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration
Number of subjects: 40
Study 24576196 — intervention group
Group type: EXPERIMENTAL
Intervention: Titration and No Titration
Number of subjects: 40
Study 23536105 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline plus intensive smoking cessation counseling
Number of subjects: 294